Paper35599264
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.
Dayyani F and 6 others. Med Oncol, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Papers, record 35599264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35599264
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Esophageal Neoplasms | Major topic |
| Irinotecan | Major topic |
| Stomach Neoplasms | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | |
| Drug Combinations | |
| Humans | |
| Platinum | |
| Pyrrolidines | |
| Thymine | |
| Trifluridine |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA062203 | NCI NIH HHS | United States | P30CA062203 | PubMed and NIH | NIH RePORTER |
| P30 CA093373 | NCI NIH HHS | United States | P30CA093373 | PubMed and NIH | NIH RePORTER |
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35202974 | FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/35202974 | PubMed |
| 2 | 27664260 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27664260 | PubMed |
| 3 | 24078663 | Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2013 | https://conductscience.org/library/papers/24078663 | PubMed |
| 4 | 33264544 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33264544 | PubMed |
| 5 | 30234181 | Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. | JCO Precis Oncol | 2018 | https://conductscience.org/library/papers/30234181 | PubMed |
| 6 | 23192279 | A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. | Cancer Chemother Pharmacol | 2013 | https://conductscience.org/library/papers/23192279 | PubMed |
| 7 | 32083013 | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. | Front Oncol | 2019 | https://conductscience.org/library/papers/32083013 | PubMed |
| 8 | 25240821 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/25240821 | PubMed |
| 9 | 32901938 | Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk? | J Surg Oncol | 2020 | https://conductscience.org/library/papers/32901938 | PubMed |
| 10 | 29543932 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29543932 | PubMed |
| 11 | 25751757 | Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. | Acta Oncol | 2015 | https://conductscience.org/library/papers/25751757 | PubMed |
| 12 | 24190112 | Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/24190112 | PubMed |
| 13 | 21573742 | Japanese gastric cancer treatment guidelines 2010 (ver. 3). | Gastric Cancer | 2011 | https://conductscience.org/library/papers/21573742 | PubMed |
| 14 | 27795561 | A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. | Leukemia | 2017 | https://conductscience.org/library/papers/27795561 | PubMed |
| 15 | 32612955 | Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/32612955 | PubMed |
| 16 | 32437664 | First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32437664 | PubMed |
| 17 | 24094768 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. | Lancet | 2014 | https://conductscience.org/library/papers/24094768 | PubMed |
| 18 | 24330513 | FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. | J Exp Clin Cancer Res | 2013 | https://conductscience.org/library/papers/24330513 | PubMed |
| 19 | 30355453 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/30355453 | PubMed |
| 20 | 20602191 | Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. | Gastric Cancer | 2010 | https://conductscience.org/library/papers/20602191 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 34175675 | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. | ESMO Open | 2021 | https://conductscience.org/library/papers/34175675 |
Source PubMed
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35599264
GET https://conductscience.org/api/papers/v1/35599264/references?page=2